go-v.orgdoi

A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma

C. Lance Cowey · Clinical Investigation · 2012

  • DOI 10.4155/cli.12.85
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2012

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2012

Abstract

The therapeutic landscape of metastatic melanoma has recently moved from the dark ages to a period of renewed hope. Until recently, treatment options for patients with this devastating disease have had limited activity with no therapy resulting in an improvement in survival. The year 2011 triggered a new dawn for melanoma therapeutics with two novel agents receiving regulatory approval. With the approval of vemurafenib, a first-in-class inhibitor of BRAF V600E mutant melanoma, and ipilimumab, a first-in-class CTLA-4 inhibitor, we now have two agents that improve survival for patients with this devastating disease.

Additionally, several agents are currently in development and hold promise to further advance clinical outcomes for patients.

Open the resolved locator · 10.4155/cli.12.85

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:30 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.12.85
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.